Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/45414
metadata.artigo.dc.title: | Vitamin D and survival in COVID-19 patients: a quasi-experimental study |
metadata.artigo.dc.creator: | Annweiler, Cédric Hanotte, Bérangère Grandin de l’Eprevier, Claire Sabatier, Jean-Marc Lafaie, Ludovic Célarier, Thomas |
metadata.artigo.dc.subject: | COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vitamin D Therapeutics Quasi-experimental study Older adults |
metadata.artigo.dc.publisher: | Elsevier |
metadata.artigo.dc.date.issued: | Nov-2020 |
metadata.artigo.dc.identifier.citation: | ANNWEILER, C. et al. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. The Journal of Steroid Biochemistry and Molecular Biology, [S.l.], v. 204, Nov. 2020. |
metadata.artigo.dc.description.abstract: | Vitamin D may be a central biological determinant of COVID-19 outcomes. The objective of this quasi-experimental study was to determine whether bolus vitamin D3 supplementation taken during or just before COVID-19 was effective in improving survival among frail elderly nursing-home residents with COVID-19. Sixty-six residents with COVID-19 from a French nursing-home were included in this quasi-experimental study. The “Intervention group” was defined as those having received bolus vitamin D3 supplementation during COVID-19 or in the preceding month, and the “Comparator group” corresponded to all other participants. The primary and secondary outcomes were COVID-19 mortality and Ordinal Scale for Clinical Improvement (OSCI) score in acute phase, respectively. Age, gender, number of drugs daily taken, functional abilities, albuminemia, use of corticosteroids and/or hydroxychloroquine and/or antibiotics (i.e., azithromycin or rovamycin), and hospitalization for COVID-19 were used as potential confounders. The Intervention (n = 57; mean ± SD, 87.7 ± 9.3years; 79 %women) and Comparator (n = 9; mean, 87.4 ± 7.2years; 67 %women) groups were comparable at baseline, as were the COVID-19 severity and the use of dedicated COVID-19 drugs. The mean follow-up time was 36 ± 17 days. 82.5 % of participants in the Intervention group survived COVID-19, compared to only 44.4 % in the Comparator group (P = 0.023). The full-adjusted hazard ratio for mortality according to vitamin D3 supplementation was HR = 0.11 [95 %CI:0.03;0.48], P = 0.003. Kaplan-Meier distributions showed that Intervention group had longer survival time than Comparator group (log-rank P = 0.002). Finally, vitamin D3 supplementation was inversely associated with OSCI score for COVID-19 (β=-3.84 [95 %CI:-6.07;-1.62], P = 0.001). In conclusion, bolus vitamin D3 supplementation during or just before COVID-19 was associated in frail elderly with less severe COVID-19 and better survival rate. |
metadata.artigo.dc.identifier.uri: | https://www.sciencedirect.com/science/article/pii/S096007602030296X http://repositorio.ufla.br/jspui/handle/1/45414 |
metadata.artigo.dc.language: | en_US |
Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.